Zydus Nycomed API site to start production in December

By Nick Taylor

- Last updated on GMT

Related tags Active ingredient

Zydus Nycomed expects commercial production at its newly commissioned API plant in Navi Mumbai, India to begin in December 2010.

Expansion of active pharmaceutical ingredients (API) capabilities at Zydus Nycomed, a 50:50 joint venture between Zydus Cadila and Nycomed, advances the plant the beyond its original purpose as a provider of key starting materials.

The site was established to provide starting materials used in production of pantoprazole, an API used in a gastrointestinal treatment marketed by Nycomed. Now, with the addition of pantoprazole API production capabilities, the site has end-to-end manufacturing capabilities.

Initially production will be limited to pantoprazole, urapidil and lornoxicam but Zydus Nycomed plans to start manufacturing an additional eight API by 2011.

Pankaj Patel, chairman and managing director at Zydus Cadila, said: “This milestone marks a new beginning in the partnership that has been evolving and growing from strength to strength over the years​.”

Expanding production capabilities builds on work done at the joint venture since it formed in 1998 to give Nycomed another API supply source for its portfolio of branded generic products.

Zydus Nycomed intends to have the site audited by the European Medicines Agency (EMA) and other international regulatory agencies. Completion of this process will make the Navi Mumbai site a global hub for supplying APIs to Nycomed for its branded generic portfolio.

Having a time-tested and solid partnership in place, like we have with Zydus Cadila, gives me confidence we will continue to achieve our goal of getting medicines that matter to those who need them​”, said Håkan Björklund, CEO of Nycomed.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...